

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 6 January 2016 from 10am to 5pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler (Chair)	Present for all notes
	2. Professor Ken Stein (Vice-Chair)	Present for all notes
	3. Dr Ray Armstrong	Present for all notes
	4. Dr Jeff Aronson	Present for all notes
	5. Professor John Cairns	Present for all notes
	6. Dr Neil Iosson	Present for all notes
	7. Dr Rebecca Kearney	Present for all notes
	8. Dr Sanjay Kinra	Present for all notes
	9. Dr Miriam McCarthy	Present for all notes
	10. Mr Christopher O'Regan	Present for all notes
	11. Dr Sanjeev Patel	Present for all notes
	12. Professor John Pounsford	Present for all notes
	13. Dr Danielle Preedy	Present for all notes
	14. Mr Alun Roebuck	Present for all notes
	15. Dr Nigel De-Kare Silver	Present for all notes
	16. David Thomson	Present for all notes
	17. Dr Nicky Welton	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Victoria Kelly	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 20
Dr Rosie Lovett	Technical Adviser,	Present for notes 1 to 20

	National Institute for Health and Clinical Excellence	
Sophie Laurenson	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 21 to 33
Raisa Sidhu	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 21 to 33
Ben Kearns	Research Associate, School of Health and Related Research, University of Sheffield	Present for notes 1 to 18
Abdullah Pandor	Research Fellow / Systematic Reviewer, School of Health and Related Research, University of Sheffield	Present for notes 1 to 18
Professor Matt Stevenson	Technical Director, School of Health and Related Research, University of Sheffield	Present for notes 1 to 18
Dr Amit Bahl	Consultant Clinical Oncologist , Bristol Cancer Institute , nominated by British Uro-Oncology Group (BUG)	Present for notes 1 to 14
Dr Zafar Malik	Consultant Clinical Oncologist , Bristol Cancer Institute , nominated by British Uro-Oncology Group (BUG)	Present for notes 1 to 14
Hugh Gunn	Trustee of TACKLE Nominated by TACKLE	Present for notes 1 to 14
Allan Higgins	Nominated by Prostate Cancer Support Organisation	Present for notes 1 to 14
Nicola Huxley	Associate Research Fellow, Peninsular Technology Assessment Group, University of Exeter	Present for notes 21 to 31
Professor Martin Hoyle	Health Economist, Peninsular Technology Assessment Group, University of Exeter	Present for notes 21 to 31
Dr Saif Mulla	Consultant in Medical Oncology nominated by Roche	Present for notes 21 to 29
Dr Vanessa Potter	Consultant GI Medical Oncologist nominated by	Present for notes 21 to 29

Stuart Barber	NCRI/RCP/RCR/ACP nominated by Beating Bowel Cancer	Present for notes 21 to 29
---------------	--	----------------------------

Non-public observers:

Helen Barnett	Medical editor, NICE	Present for notes all notes
Jacoline Bouvy	Scientific Adviser, Science Policy and Research Programme, NICE	Present for notes all notes
Paulo Dias	NICE	Present for notes 1 to 29
Geoffrey Ellison	Coordinator, Observational Data Unit	Present for notes all notes
Chloe Kastoryano	PIP Advisor, NICE	Present for notes all notes
Else-Marije Krajenbrink	Coordinator, NICE International	Present for notes 21 to 29
Linda Laryea	Assistant Research Manager – Technology Assessment Reviews (TARs), NIHR	Present for notes all notes
Hannah Patrick	Consultant Clinical Adviser, NICE	Present for notes all notes
Penny Duckham	Kaiser Foundation	Present for notes 21 to 29

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen and cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
2. The Chair welcomed Dr Rebecca Kearney back to the Committee.
3. The Chair informed the Committee that this would be Professor Ken Stein's last meeting as Vice-Chair and she thanked him for his contribution.
4. Apologies were received from Anne Joshua, Professor Ruairidh Milne, Professor Stephen Palmer and Dr Marta Soares.

Any other Business

5. The Chair gave the Committee an update on developments in other ongoing Technology Appraisals.

Appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen [ID889]

Part 1 – Open session

6. The Chair welcomed the invited experts: Dr Amit Bahl, Dr Zafar Malik, Hugh Gunn, Allan Higgins, Ben Kearns, Abdullah Pandor and Professor Matt Stevenson to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from Sanofi to the meeting.
8. The Chair asked all Committee members to declare any relevant interests
 - 8.1. Dr Amanda Adler, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Neil Iosson, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, David Thomson and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.
9. The Chair asked all NICE Staff to declare any relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.
10. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 10.1. Allan Higgins, Ben Kearns, Abdullah Pandor and Professor Matt Stevenson declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.
 - 10.2. Dr Amit Bahl declared a personal financial interest as he has received honoraria for attending meetings and advisory boards for Sanofi, Astellas, Dendreon, Janssen, Amgen, Bayer and Roche.
 - 10.2.1. It was agreed that this declaration would not prevent Dr Bahl from participating in this section of the meeting.
 - 10.3. Dr Zafar Malik declared a personal financial interest as he given commercial and research consultancy advice to Sanofi, Astellas, Janssen and Amgen in the last twelve months.
 - 10.3.1. It was agreed that this declaration would not prevent Dr Malik from participating in this section of the meeting.

- 10.4. Hugh Gunn declared a financial interest as Tackle receives grants from pharmaceutical companies.
10.4.1. It was agreed that this declaration would not prevent Mr Gunn from participating in this section of the meeting.
11. The Chair introduced the lead team, Professor John Cairns and Dr Danielle Preedy. They and the Chair gave presentations on the clinical effectiveness and cost effectiveness of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
14. The Chair then thanked the experts for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.
16. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
17. Discussion on confidential information continued.
18. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
19. The Committee continued to discuss the clinical and cost effectiveness of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.
- 19.1. The committee decision was based on consensus.
20. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of cetuximab and panitumumab for previously untreated metastatic colorectal cancer [ID794]

Part 1 – Open session

21. The Chair welcomed the invited experts: Dr Saif Mulla, Dr Vanessa Potter, Stuart Barber, Nicola Huxley and Professor Martin Hoyle to the meeting and they introduced themselves to the Committee.

22. The Chair welcomed company representatives from Amgen and Merck Serono to the meeting.
23. The Chair asked all Committee members to declare any relevant interests
 - 23.1. Dr Amanda Adler, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Neil Iosson, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, David Thomson and Dr Nicky Welton declared a non-personal specific financial interest as part of his team had produced the assessment report for this appraisal, although he had not been directly involved.
24. The Chair asked all NICE Staff to declare any relevant interests.
 - 24.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
25. The Chair asked all other invited guests (assessment group and invited experts, not including observers) to declare their relevant interests.
 - 25.1. Nicola Huxley and Professor Martin Hoyle declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
 - 25.2. Dr Saifee Mullamitha declared a personal financial interest as he has been invited to give talks and to chair meetings by Roche, Amgen and other pharmaceutical companies. He has also attended advisory boards for pharmaceutical companies and has been taken to conferences by pharmaceutical companies.
 - 25.2.1. It was agreed that this declaration would not prevent Dr Mullamitha from participating in this section of the meeting
 - 25.3. Dr Vanessa Potter declared a personal financial interest as MerckSerono provided funding for her to attend the ESMO 2014 meeting.
 - 25.3.1. It was agreed that this declaration would not prevent Dr Potter from participating in this section of the meeting
 - 25.4. Stuart Barber declared a financial interest as Beating Bowel Cancer receives funding from a number of pharmaceutical companies. He observed that this made up less than 10% of Beating Bowel Cancer's total income.
 - 25.4.1. It was agreed that this declaration would not prevent Mr Barber from participating in this section of the meeting

26. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
27. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
28. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
29. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

30. Discussion on confidential information continued. This information was supplied by the companies.
31. The Chair then thanked the Assessment Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
32. The Committee continued to discuss the clinical and cost effectiveness of cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
 - 32.1. The committee decision was based on consensus.
33. The Committee agreed to defer a decision on the content of the guidance section of the Final Appraisal Determination (FAD) until further analyses had been undertaken.

Date, time and venue of the next meeting

34. Wednesday 3 February 2016 at Prospero House, 241 Borough High Street, London, SE1 1GA